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Abstract
Background: Routes of transmission of multidrug-resistant gram-negative organisms (MDRGN) are not completely
understood. Since sexual transmission of MDRGN might represent a potential mode that has not been noticed so
far, this study evaluated transmission of MDRGN in HIV positive men.
Methods: Between November 2014 and March 2016, we retrospectively investigated the MDRGN prevalence in
rectal swabs of n = 109 males tested positive for HIV (HP). These findings were compared to the MDRGN prevalence
in n = 109 rectal swabs in age-matched males tested negative for HIV (HN) within the same period. According to
the infection control protocol of University Hospital Frankfurt, Germany (UHF), patients admitted to intensive/
intermediate care units have to be screened for MDRGN on day of admittance. Patients without HIV testing or
MDRGN screening were excluded.
Results: MDRGN prevalence in rectal swabs was significantly higher (p = 0.002) in male HP (23.9%; 95% confidence
interval 16.2–32.9%) than in age-matched male HN (8.3%; 3.8–15.1%). In total, 35 MDRGN species were detected.
The most frequent MDRGN species was Escherichia coli with resistance due to ESBL expression and additional
resistance to fluoroquinolones with n = 25/35 (71.4%; 53.7–85.4%). Thereof, n = 19/26 (73.1%; 52.2–88.4%) were
detected in HP and n = 6/9 (66.7%; 29.9–92.5%) in HN, respectively.
Conclusions: Prevalence of MDRGN is significantly higher in male HIV positive than in male HIV negative
individuals. This might indicate sexual transmission of MDRGN within the male HIV positive population. As
treatment options in case of MRGN infections are limited, prevention of MDRGN transmission is strongly
emphasized.
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Background
Multidrug–resistant gram–negative organisms (MDRGN),
which have previously been defined as Enterobacteriaceae
with extended spectrum beta–lactamase (ESBL)–pheno-
type, and Enterobacteriaceae, Acinetobacter baumannii
and Pseudomonas aeruginosa resistant against piperacillin,
any 3rd/4th generation cephalosporin, and fluoroquino-
lones +/– carbapenems [1], are frequent causes of
community and healthcare-associated infections [2, 3]. In
recent years, carbapenems became the drugs of choice for
the treatment of invasive MDRGN infections [4]. At the
same time, the consumption of carbapenems has been in-
creased dramatically [5] and the worldwide prevalence of
carbapenemase-producing organisms soon after was
found to be elevated [6, 7]. While the explosive spread of
carbapenemases has previoulsy been attributed to several
factors, such as increasing administration of carbapenems
or contact to the health care system in high-prevalence
countries (HPC) [8–10], global spread might also be fa-
vored by plasmid encoded resistance genes transfer [11].
However, comprehensive knowledge of the ways of
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transmission is still lacking. Future concise considerations
on the spread of MDRGN should therefore also evaluate
routes of transmission that have not been noticed so far.
We hypothesize that microbiota, with MDRGN might be
part of it, is exchanged during mucous membranes con-
tacts, e.g. sexual intercourse, Although the primary route
of MDRGN transmission might be different, sexual trans-
mission should therefore not dismissed. This hypothesis
has previously been confirmed by investigations on the
sexual transmission of Human Herpes Virus Type 8, E. coli
O117:H7 and Shigella spp., although the primary route of
these agents’ transmission is via saliva or feco-orally, re-
spectively [12–14]. It additionally should be taken into ac-
count that it has previously been reported that the risk to
acquire “classical” sexually transmitted diseases (STD)
such as gonorrhea or syphilis, or infection with the Hu-
man Immunodeficiency Virus (HIV) is higher in cohorts
of men who have sex with men (MSM) than for the gen-
eral population [15, 16]. This has also been demonstrated
for Germany [17, 18]. With regard to these aspects, pre–
or co–existing STD (e.g. HIV infection) have been demon-
strated to be suitable parameters to identify individuals
with previous or current unprotected, “risky” sexual inter-
course. We therefore hypothesize that MDRGN preva-
lence might be higher in patient groups with HIV
infection compared to patient groups tested negative for
HIV. In light of the persistent global spread of MDRGN,
possibly with a number of different routes, the role of sex-
ual transmission has to be clarified. We present the first
study addressing this possible transmissibility of MDRGN
by sexual intercourse.
Methods
MDRGN screening policy at University Hospital Frankfurt,
Germany
According to German infection protection law it is
mandatory for hospitals to execute documented infec-
tion control strategies to prevent the transmission of in-
fective agents and protect patient health. At University
Hospital Frankfurt, Germany (UHF), several defined pa-
tient risk groups are screened for MDRGN and methicil-
lin resistant Staphylococcus aureus (MRSA) on day of
admittance, such as patients admitted to intensive/inter-
mediate care units (ICU/IMC) at UHF. This means, that
each patient will get screened in case of admittance to
ICU/IMC at UHF independently from his medical
diagnosis.
Patients and specimens
We retrospectively identified and included adult individ-
uals having had both a rectal screening for MDRGN and
HIV testing between November 2014 and March 2016.
Patients having had only one of the parameters (screen-
ing for MDRGN or testing for HIV) were excluded from
this study. Patients tested positive for HIV and having
had a rectal screening for MDRGN qualified for the case
cohort, hereinafter referred to as HP. Vice versa, patients
tested negative for HIV and having had a rectal screen-
ing for MDRGN qualified for the control cohort, herein-
after referred to as HN.
Identification of cases (HP) and controls (HN) was per-
formed as follows. First, individuals serologically tested
positive for HIV and admitted to the department for In-
ternal Medicine II/Infectious Diseases at UHF were identi-
fied. Subsequently, these patients were evaluated for being
routinely screened for MDRGN during the observation
period according to the infection control protocol of UHF.
Control patients who were tested serologically negative
for HIV and admitted to any department at UHF were also
evaluated for being routinely screened for MDRGN during
the observation period. Cases and controls were matched
on +/- 2 years. By this approach, n = 109 male HP and
male HN each qualified for this study. Additionally, digital
patient data files were evaluated to stratify patients’ gen-
eral groups of diseases. Furthermore, the stadium of HIV
infection was defined according to CDC criteria [19] of all
the patients admitted to the department of Internal Medi-
cine II/Infectious Diseases. With regard to the pilot char-
acter of this study and small number of individuals who
meet inclusion criteria, co-morbidities and previous anti-
biotic use were not considered in sampling.
Detection of MDRGN and molecular resistance analysis
The results for the patients’ MDRGN status were retro-
spectively investigated. For the investigation, we performed
a proven methodical procedure that has formerly been pub-
lished [1]. During the retrospective observation period, all
laboratory testing procedures were performed by the Insti-
tute for Medical Microbiology and Infection Control at
UHF under strict quality–controlled criteria (laboratory ac-
creditation according to ISO 15189:2007 standards; certifi-
cate number D–ML–13102–01–00, valid through January
25th, 2021). Rectal swabs were collected using culture
swabs with Amies collection and transport medium (Hain
Lifescience, Nehren, Germany) and streaked onto selective
CHROMagar™ ESBL plates (Mast Diagnostica, Paris,
France). Identification of presumed MDRGN species was
done by matrix-assisted–laser desorption ionization–time
of flight analysis (MALDI–TOF; VITEK MS, bioMérieux,
Nürtingen, Germany). Antibiotic susceptibility testing
was performed according to Clinical and Laboratory
Standards Institute (CLSI) guidelines using VITEK 2
and/or antibiotic gradient tests (bioMérieux) where
necessary. In case of gram-negative carbapenem-
resistant isolates, detection of genes encoding carba-
penemases were routinely performed via PCR analysis
and subsequent sequencing from carbapenem resistant
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Enterobacteriaceae including the bla genes for the fol-
lowing carbapenemases: NDM, VIM, IMP, OXA–48,
and KPC [10, 11, 20].
Detection of HIV-1/2 antibodies
Considering that HIV positivity has been suggested to
be a marker for a risky sexual behaviour [20], we retro-
spectively evaluated the HIV status of each individual by
examination of the patient files. HIV testing was only
performed if medically indicated by physicians at UHF.
Laboratory HIV testing was performed by Institute for
Medical Virology at UHF under strict quality–controlled
criteria (laboratory accreditation according to ISO–
15189:2007 standards; certificate number D–ML–13102–
03–00 valid through 08.12.2018). All serum samples had
been previously screened with the HIV antigen/antibody
(Ag/Ab) Combo Screening Assay (Abbott, Delkenheim,
Germany; Architect System; REF 4 J27) working with the
Architect system detecting HIV–1/2 antibodies and HIV–
1 p24 antigen. Samples with reactive screening assay re-
sults (positive, indeterminate) were further evaluated using
the western blot New Bio-Rad LAV–Blot I and LAV–Blot
II (Bio–Rad Laboratories GmbH, München, Germany),
which uses native HIV proteins. The assay was performed
as outlined in guidelines provided by the manufacturer.
Statistical analysis
Sample size of n = 109 individuals per group proved to be
adequate by a power = 0.95 and Cohen’s d = 0.5. Chi
squared test was performed for statistical analysis. 95%
confidence intervals (95% CI) for frequencies were calcu-
lated based on binomial distribution and used to confirm
statistical significance. P-values ≤ 0.05 were considered as
statistically significant.
Results
In the current study, we evaluated n = 109 male HP and
n = 109 male HN, respectively, admitted to UHF be-
tween November 2014 and March 2016. Both the male
HPs’ and male HNs’ median age was 46 years, the stand-
ard deviation being 10.8 and 11.0 years, respectively.
Table 1 shows the general groups of diseases HP and
HN they were admitted for to UHF. In HP, the most fre-
quent group were patients admitted to the department
of Internal Medicine II/Infectious Diseases with 82.6%
(n = 90/109). HN were most frequently admitted to UHF
due to oncological diseases with 39.4% (n = 43/109).
Among male HP and male HN, a total of n = 35
MDRGN isolates were detected. Thereof, n = 26/109 and
n = 9/109 rectal swabs were positive for any MDRGN in
male HP and male HN, respectively, which resulted in
an overall MDRGN prevalence of 23.9% (16.2–32.9) in
male HP and a significantly (p = 0.002) lower MDRGN
prevalence in male HN with 8.3% (3.8–15.1). Looking
into the single proportions of the detected MDRGN, no
significant differences were detected between male HP
and HN patients, respectively (Fig. 1).
The most frequently detected species within the
MDRGN isolates (n = 35 in total) was E. coli with resist-
ance due to ESBL expression and additional resistance
to fluoroquinolones (E. coli ESBL/FQ) with n = 25/35
(71.4%; 53.7–85.3). Thereof, E. coli ESBL/FQ was de-
tected in n = 19/26 (73.1%; 52.2–88.4%) of male HP and
Table 1 General group of diseases HIV positive (HP) patients
and HIV negative (HN) patients were admitted for to University
Hospital Frankfurt, Germany (UHF), as given by the digital
patient data files
HP HN
General characteristics
Number of patients (n) 109 109
Male (%) 100 100
Mean age and standard
deviation (years)
46 (10.8) 46 (11.0)
General group of diseases
patients were admitted
for to UHF
Department for Infectious
diseases (n;%)
90 (82.6) 12 (11.0)
Stadium of HIV
infection a(n;%)
A1 8; 8.9 -
A2 16; 17.8
A3 5; 5.6
B1 -
B2 4; 4.4
B3 7; 7.8
C1 -
C2 5; 5.6
C3 40; 44.4
unknown 5; 5.6
Hematology/Oncology (n;%) 6; 5.6 43 (39.4)
Gastroenterology (n;%) 3; 2.8 14 (12.8)
Pneumology (n;%) 1; 0.9 2 (1.8)
Cardiology (n;%) - 3 (2.7)
Nephrology (n;%) - 7 (6.4)
Rheumatology (n;%) - 1 (1)
Neurology 5; 4.6 5 (4.6)
General surgery and
traumatology (n;%)
4; 3.7 21 (19.3)
Neurosurgery (n;%) - 1 (1)
Abbreviations: UHF University Hospital Frankfurt am Main, Germany; HIV human
immunodeficiency virus
aas defined by CDC [19]: A = asymptomatic, acute HIV, or persistent
generalized lymphadenopathy; B = symptomatic conditions, not A or C; C =
AIDS-indicator conditions; “1” CD4+ cell count ≥ 500/μl; “2” = CD4+ cell count
200-499/μl; “3” = CD4+ cell count <200/μl (in detail see [19])
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in n = 6/9 (66.7%; 29.9–92.5%) of male HN (p = 0.713),
respectively. All MDRGN detected in male HP and male
HN are depicted by in Table 2. None of the bacterial
species P. aeruginosa or A. baumannii and neither, no
resistance to carbapenems were detected in any of the
isolates from male HN nor any of HP.
Discussion
In light of the explosive global spread of MDRGN, atten-
tion must be directed to potential routes of transmission
that have not been recognized so far. Several routes of
transmission, e.g. traveling in HPC [8], antibiotic selective
pressure [5], or transmission by livestock [21] have previ-
ously been demonstrated. However, to our knowledge this
is the first study focusing on the potential transmission of
MDRGN in male HIV positive individuals.
The prevalence of MDRGN in male HN amounted to
8.3% (3.8–15.1; Table 2). This value does not substan-
tially deviate from the prevalence of ESBL of about 6.3%
in clinical specimen, which has formerly been described
to be 6.3% by a German cross–sectional study [22].
However, the prevalence of MDRGN in rectal swabs of
male HP (23.9%; 16.2–32.9) exceeded the value investi-
gated by Valenza et al. [22] by almost three-fold. These
findings suggest that HIV positive men might be more
susceptible to acquire MDRGN. Furthermore, our find-
ings indicate a pre–dominance of E. coli ESBL/FQ
(Table 1), it might therefore be interesting to
characterize these E. coli-isolates isolated from male HP
further for expression of pathogenicity factors, e.g. type
1 fimbriae (fimH), pili associated with pyelonephritis
(pap), S and F1C fimbriae (sfa and foc), afimbrial adhe-
sins (afa), cytotoxic necrotizing factor (cnf ), hemolysin
(hly) or aerobactin (aer) using molecular techniques [23]
and subsequently compare these findings with isolates
collected from HN. We therefore feel it is warranted to
further characterize MDRGN isolates isolated from HP
and HN by molecularbiological methods, preferentially
by whole genome sequencing (WGS).
Although no significant differences in proportion of
any single MDRGN species were observed (Table 2), this
might indicate that the sexual route of transmission is
apparently not preferred by any particular MDRGN spe-
cies. It rather might be interpreted as a general inherent
Fig. 1 Prevalence (%) of multidrug-resistant gram-negative organisms (MDRGN) in patients tested positive (HP) and negative for HIV (HN). 95%
confidence intervals are marked as ranges; percentage and 95% confidence intervals are given
Table 2 Prevalence of multidrug-resistant gram-negative organisms
in males tested positive for HIV and males tested negative for HIV
HP HN
Number of patients (n) 109 109
Median age and
standard deviation (years)
46; 10.8 46; 11.0
Tested positive for MDRGN
(%; 95% CI; n)
23.9; 16.2–32.9; 26 8.3; 3.8–15.1; 9
Total number of MDRGN
isolates (n)
35
Thereof (n) 26 9
E. coli ESBL/FQ (%; 95%CI; n) 73.1; 52.2–88.4; 19 66.7; 29.9–92.5; 6
E. coli ESBL (%; 95%CI; n) 23.1; 8.9–43.6; 6 11.1; 0.3–48.3; 1
K. pneumoniae ESBL/FQ
(%; 95%CI; n)
3.8; 0.0–19.6; 1 22.2; 2.8–60.0; 2
MDRGN with resistance to
carbapenems
0 0
Abbreviations: HIV human immunodeficiency virus; HP males tested positive for
infection with HIV; HN males tested negative for infection with HIV; MDRGN
multidrug-resistant gram-negative organism. E. coli ESBL: resistant due to ESBL
expression; E. coli/K. pneumoniae ESBL/FQ: ESBL and resistance
to fluoroquinolones
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risk to acquire a MDRGN. Since the sexual route of
transmission of MDRGN has not been suggested so far,
this is as important finding of this study. However, sev-
eral epidemiological events give an impression that sex-
ual spread of organisms is possible, although their
preferred way of transmission is reported to be non-
sexual: Shigella sonnei, which is either none of the “clas-
sical” STD-causing organisms, has been shown to spread
among men who have sex with men (MSM) in Montréal,
Canada, and Germany [24, 25] the verocytotoxin-
producing EHEC O117:H7 has also been documented to
spread among MSM in Great Britain [16] and, as well,
no “classical” STD, meningococcal serogroup C diseases
has newly been shown to spread among MSM [26, 27].
This outlines that sexual transmission of Enterobacteria-
ceae is distinctly possible via translocation of intestinal
bacteria. Sexual transmission of MDRGN is therefore
suggested not to be dismissed in future comprehensive
considerations on MDRGN transmission prevention.
However, the link between HIV positivity and risky
sexual behavior must be interpreted diligently: if positive
HIV serology might indicate that the patient has previ-
ously had a risky behavior (and HIV was not contracted
e.g. by blood transfusion), this may have lasted for years
up to now, or it may have ended in the meanwhile. The
time of carriage of MDRGN might be short [28] and we
therefore cannot ascertain that the timeframes between
the risky behavior and MDRGN acquisition could coin-
cide. However, at this time we did not see any alternative
assessment available to clarify the potential route of sex-
ual transmission.
Concerning that data regarding the history of previous
hospital stays nor antibiotic pre–treatment for male HP
and male HN were not evaluated, it is not possible to
confirm that male HP in the UHF–setting might have
had a stronger history of antibiotic pre–treatment than
male HN. Considering that all patients enrolled in this
investigation matched the requirement to be screened
for MDRGN (which is usually limited to patients admit-
ted to ICU or IMC at UHF), this might indicate that
both male HP and male HN had a recent history of anti-
biotic treatment. However, HIV patients in particular
might have undergone a prexisiting antibiotic pressure
due to their HIV infection (e.g. administration of cotri-
moxazole to treat Pneumocystis jirovecii pneumonia) and
might therefore have a higher risk for admittance to hos-
pitals and health care facilities where nosocomial
MDRGN transmissions can occur [29]. These aspects
might therefore have introduced a source of biases in
the selection of patients.
However, not also antibiotic treatment, but also pre–
existing co-morbidities also might be an aspect that has
to be evaluated in a future setting to round off investiga-
tions on conditions of sexual transmission of MDRGN.
Since gastrointestinal diseases or co-infections might com-
promise the gastrointestinal mucosa, this might promote
the transmission of MDRGN. As such interrelation has
formerly been shown for amebiasis and HIV [30], this as-
pect should not be neglected.
Furthermore, it remains open to question whether
these findings are also valid for women. As urinary tract
infections (UTI) are one of the most common (usually
endogenous) bacterial infections often triggered by sex-
ual intercourse, and many women suffer from at least
one UTI during their lifetime [31], in a future setting the
prevalence of MDRGN should be investigated in uro-
genital and/or vaginal swabs in female cohorts.
Conclusions
Our study demonstrated that prevalence of MDRGN in
HIV positive male individuals is significantly higher than
in HIV negative male individuals. Although no significant
differences in proportion of any single MDRGN species
were observed, this indicates that sexual transmission of
MDRGN within the male HIV positive population is pos-
sible. With regard to the results of this study, practicing
safer sex should be propagated actively further on to re-
duce not only the spread of many STD-associated patho-
gens but most likely also MDRGN.
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